医学
多发性骨髓瘤
人口
介绍
流行病学
疾病
概化理论
内科学
重症监护医学
临床试验
家庭医学
环境卫生
数学
统计
作者
Moritz Binder,Bharat Nandakumar,S. Vincent Rajkumar,Prashant Kapoor,Francis K. Buadi,David Dingli,Martha Q. Lacy,Morie A. Gertz,Suzanne R. Hayman,Nelson Leung,Amie Fonder,Miriam Hobbs,Yi L. Hwa,Eli Muchtar,Rahma Warsame,Taxiarchis Kourelis,Wilson I. Gonsalves,Stephen J. Russell,Yi Lin,Mustaqeem Siddiqui,Robert A. Kyle,Angela Dispenzieri,Shaji Kumar
出处
期刊:Leukemia
[Springer Nature]
日期:2021-10-26
卷期号:36 (3): 801-808
被引量:45
标识
DOI:10.1038/s41375-021-01453-5
摘要
Advances in the understanding of disease biology, drug development, and supportive care have led to improved outcomes in multiple myeloma. Given that these improvements have been reported in clinical trial and referral center populations, questions remain about the generalizability of this observation to patients treated in the community. Contrasting the overall survival experience of 3783 patients seen at Mayo Clinic and 57,654 patients followed in the Surveillance, Epidemiology, and End Results Program (SEER) between 2004 and 2018, we observed different mortality trends across patient populations and subgroups. Early mortality decreased and estimated 5-year overall survival increased over time in both patient populations. Excess mortality (compared to the general population) declined over time in Mayo Clinic patients and remained largely unchanged in SEER patients. Improvements over time were primarily observed in patients with favorable disease characteristics and older patients with multiple myeloma remain a vulnerable population with significant excess mortality compared to the United States general population. Patients with unfavorable disease characteristics have derived disproportionately less benefit from recent advances in the field. Future efforts need to focus on the development of safe and effective therapies for these patients and on increasing timely access to specialized care for patients in the community.
科研通智能强力驱动
Strongly Powered by AbleSci AI